Научно-практическая ревматология | |
PROSPECTS FOR ANTI-B-CELL THERAPY IN RHEUMATOLOGY | |
E. L. Nasonov1  | |
[1] V.A. Nasonova Research Institute of RheumatologyDepartment of Rheumatology, Institute of Professional Education, I.M. SechenovFirst Moscow State Medical University (Sechenov University); | |
关键词: autoimmune diseases; b-cells; rituximab; belimumab; rheumatoid arthritis; systemic lupus erythematosus; | |
DOI : 10.14412/1995-4484-2018-539-548 | |
来源: DOAJ |
【 摘 要 】
Impaired B-cell immunological tolerance plays a central role in the pathogenesis of autoimmune rheumatic diseases and autoimmune diseases of another nature. B-cells link innate and acquired immunity: they express Toll-like receptors that respond to danger signals; act as antigen-presenting cells; induce an antigen-specific immune response; determine the development of immunological memory; and synthesize a wide range of cytokines that regulate (stimulate or suppress) an immune response and inflammation. In autoimmune diseases, there are metabolic and B-cellular signaling disturbances that lead to defects in B-regulatory, T-regulatory, follicular T-helper, and dendritic cells. B-cells synthesize organ-nonspecific and organ-specific autoantibodies that are biomarkers for autoimmune diseases and play in important role in their immunopathogenesis. Anti-B-cell therapy that causes B-cell depletion in blood and target organs is effective in a wide range of autoimmune diseases. Its efficiency is determined by various mechanisms, such as suppression of pathogenic autoantibody synthesis; modulation of the function of B-cells (antigen presentation, cytokine synthesis, and costimulation), T-lymphocytes and dendritic cells. Further study of a strategy for targeted anti-B-cell therapy, mechanisms of action, and new targets is important for the progress of modern rheumatology to improve the treatment strategy of autoimmune rheumatic diseases.
【 授权许可】
Unknown